Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Clindamycin Phosphate Foam, 1%. Glenmark’s Clindamycin Phosphate Foam, 1 percent is bioequivalent and therapeutically equivalent to the reference listed drug, Evoclin®2 Foam, 1 percent, of Mylan Pharmaceuticals Inc.

According to IQVIATM sales data for the 12-month period ending December 2024, the Evoclin® Foam, 1 percent market3 achieved annual sales of approximately USD 5.8 million.

Glenmark Pharmaceuticals Ltd. is a research?led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology, and oncology. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. Scrip 100 positions Glenmark amongst the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023; while Generics Bulletin places it in the Top 50 Generics and biosimilar companies ranked by sales in 2024.

Glenmark’s Green House Gas (GHG) emission reduction targets have been approved in 2023 by the Science Based Target initiative (SBTi), making it only the second pharmaceutical company in India to achieve this. The organization has impacted over 3.3 million lives over the last decade through its CSR interventions.